News

EyeGate Pharma (EyeGate) has completed phase II study of its lead product candidate, EGP-437, for the treatment of anterior uveitis. In the study, EGP-437, a corticosteroid solution specifically

Graffinity Pharmaceuticals (Graffinity) has entered into a drug discovery research collaboration with Genentech, a wholly-owned member of the Roche Group. With this collaboration Genentech is expected to gain

The European regulatory authorities have approved Medivir’s marketing authorisation application in 14 European countries. The trademark for the product in Europe will be Xerclear. The company has claimed

Threshold Pharmaceuticals and Eleison Pharmaceuticals have executed a licensing agreement granting Eleison Pharmaceuticals exclusive worldwide rights to glufosfamide. Reportedly, Glufosfamide is a novel small molecule that has been

“Prometheus has a long and successful history of providing innovative diagnostics that complement targeted therapeutics to help physicians individualize patient care,” said Joseph M. Limber, president and chief

Inovio Biomedical (Inovio) has initiated phase I clinical study of Pennvax-B preventive DNA vaccine delivered using its proprietary electroporation technology. The multi-center study will be conducted at several

Evotec has extended its current research collaboration with Ono Pharmaceutical (Ono) and initiated a new discovery collaboration. Under the contract extension Evotec will provide integrated drug discovery activities,

Radient Pharmaceuticals (Radient) has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics (ADI) with CeTeCancer to validate the effectiveness of its Onko-Sure in vitro

Celsion Corporation (Celsion) has received approval from China’s State Food and Drug Administration (SFDA) for its Clinical Trial Application for ThermoDox that permits Celsion to include Chinese clinical